Figure 5

MIRA-1 in combination with current anti-myeloma agents displayed synergistic cytotoxic response in MM cells. Cells obtained from either cell lines or patient samples were treated with MIRA-1 (10 μmol l⁻¹) in combination with (A) dexamethasone (1.0 μmol l⁻¹) or (B) doxorubicin (1.0 μmol l⁻¹). (C) MM.1S or U266 cells were treated with MIRA-1 (5 μmol l⁻¹) and velcade (2.5 nmol l⁻¹). 48 h after treatment, cells were assessed for survival by MTT viability assay (*<0.05). Data are expressed as mean ± s.d. of triplicate cultures of at least two independent experiments.